Replies to post #207669 on Biotech Values

[DewDiligence]

EGRX -7% on TEVA's 2017 guidance for combined Bendeka/Treanda sales of $600-$660M, which is less than Treanda alone sold in 2016.

[DewDiligence]

TEVA’s 2017-outlook slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNDU3MjJ8Q2hpbGRJRD02NTYzMTg=

Slide #14 speaks to Copaxone.

[gfp927z]

Dew, Any thoughts on where the bottom might be for Teva? I'm figuring it will test key support at 30, but that's only based on a cursory analysis of the chart. Sure is tempting at these levels, but needs to find a base.

Any thoughts on the company's fundamental prospects? Thanks for any insights.